申请人:Enanta Pharmaceuticals, Inc.
公开号:US11352363B1
公开(公告)日:2022-06-07
The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof:
which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable slat thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.
本发明公开了式(Ia)化合物及其药学上可接受的盐类:
其可抑制冠状病毒的复制活性。本发明进一步涉及包含式(Ia)化合物或其药学上可接受的片剂的药物组合物,以及治疗或预防有需要的受试者感染冠状病毒的方法,包括向受试者施用治疗有效量的式(Ia)化合物或其药学上可接受的盐。